Non-COVID-19 RCT 180 patients with acute viral pharyngitis, predominantly caused by human rhinovirus (HRV), showing symptom improvement and viral load reduction with iota-carrageenan lozenges compared to placebo. Patients receiving lozenges (6 daily for up to 10 days) reported faster symptom relief based on Jackson's Total Symptom Score, particularly between days 2 and 4. Human rhinovirus (HRV)-positive participants experienced a 90.2% viral load reduction versus 72.0% in the placebo group by day 5. Adverse events were minimal and similar across groups, with mild throat irritation being most common.
Iota-carrageenan works by binding to viral particles and preventing attachment to host cells. This mechanism is not virus-specific and has shown broad-spectrum activity against other respiratory viruses, including coronaviruses and SARS-CoV-2, in preclinical studies. Lozenges provide targeted delivery to the throat, a key site of viral replication in early COVID-19. This localized action could help reduce viral load in the upper respiratory tract, potentially impacting transmission and disease progression.
Karna et al., 30 Dec 2024, Double Blind Randomized Controlled Trial, placebo-controlled, peer-reviewed, 2 authors.
Antiviral Efficacy of Iota-Carrageenan Lozenges in Treating Acute Viral Pharyngitis: A Randomized Controlled Study
Dr Samiksha Karna, Dr Abhay D Havle
Journal of Neonatal Surgery, doi:10.52783/jns.v13.1432
Iota-carrageenan, acute viral pharyngitis
References
Cherian, Potdar, Jadhav, Yadav, Gupta et al., Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India, bioRxiv,
doi:10.1101/2021.04.22.440932
Collier, Marco, Ferreira, Meng, Datir et al., Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies, Nature,
doi:10.1038/s41586-021-03461-y
Davies, Abbott, Barnard, Jarvis, Kucharski et al., Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England, Science,
doi:10.1126/science.abg3055
Galloway, Paul, Maccannell, Johansson, Brooks et al., Emergence of SARS-CoV-2 B.1.1.7 Lineage-United States, MMWR Morb. Mortal. Wkly. Rep,
doi:10.15585/mmwr.mm7003e2
Hou, Okuda, Edwards, Martinez, Asakura et al., SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract, Cell,
doi:10.1016/j.cell.2020.05.042
Kim, Jang, Soh, Lee, Lee, The Impact on infectivity and neutralization efficiency of SARS-CoV-2 lineage B.1.351 pseudovirus, Viruses,
doi:10.3390/v13040633
Korber, Fischer, Gnanakaran, Yoon, Theiler et al., Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus, Cell,
doi:10.1016/j.cell.2020.06.043
Little, Read, Amlôt, Chadborn, Rice et al., Reducing risks from coronavirus transmission in the home-the role of viral load, BMJ,
doi:10.1136/bmj.m1728
Meng, Kemp, Papa, Datir, Ferreira et al., Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7, Cell Rep,
doi:10.1016/j.celrep.2021.109292
Mwenda, Saasa, Sinyange, Busby, Chipimo et al., Detection of B.1.351 SARS-CoV-2 Variant Strain-Zambia
Planas, Veyer, Baidaliuk, Staropoli, Guivel-Benhassine et al., Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization, Nature,
doi:10.1038/s41586-021-03777-9
Tegally, Wilkinson, Giovanetti, Iranzadeh, Fonseca et al., Detection of a SARS-CoV-2 variant of concern in South Africa, Nature,
doi:10.1038/s41586-021-03402-9
Volz, Mishra, Chand, Barrett, Johnson et al., Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England, Nature,
doi:10.1038/s41586-021-03470-x
Wang, Casner, Nair, Wang, Yu et al., Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization, bioRxiv,
doi:10.1101/2021.03.01.433466
Wibmer, Ayres, Hermanus, Madzivhandila, Kgagudi et al., SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma, Nat. Med,
doi:10.1038/s41591-021-01285-x